PortalPublikationenAllogeneic hematopoietic stem cell transplantation (allo SCT...

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

Standard

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. / Saussele, Susanne; Lauseker, Michael; Gratwohl, Alois; Beelen, Dietrich W; Bunjes, Donald; Schwerdtfeger, Rainer; Kolb, Hans-Jochem; Ho, Anthony D; Falge, Christiane; Holler, Ernst; Schlimok, Gunter; Zander, Axel R.; Arnold, Renate; Kanz, Lothar; Dengler, Robert; Haferlach, Claudia; Schlegelberger, Brigitte; Pfirrmann, Markus; Muller, Martin C; Schnittger, Susanne; Leitner, Armin; Pletsch, Nadine; Hochhaus, Andreas; Hasford, Joerg; Hehlmann, Ruediger.

in: BLOOD, Jahrgang *115*, Nr. 10, 10, 2009, S. 1880-1885.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Saussele, S, Lauseker, M, Gratwohl, A, Beelen, DW, Bunjes, D, Schwerdtfeger, R, Kolb, H-J, Ho, AD, Falge, C, Holler, E, Schlimok, G, Zander, AR, Arnold, R, Kanz, L, Dengler, R, Haferlach, C, Schlegelberger, B, Pfirrmann, M, Muller, MC, Schnittger, S, Leitner, A, Pletsch, N, Hochhaus, A, Hasford, J & Hehlmann, R 2009, 'Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.', BLOOD, Jg. *115*, Nr. 10, 10, S. 1880-1885. <http://www.ncbi.nlm.nih.gov/pubmed/19965667?dopt=Citation>

APA

Saussele, S., Lauseker, M., Gratwohl, A., Beelen, D. W., Bunjes, D., Schwerdtfeger, R., Kolb, H-J., Ho, A. D., Falge, C., Holler, E., Schlimok, G., Zander, A. R., Arnold, R., Kanz, L., Dengler, R., Haferlach, C., Schlegelberger, B., Pfirrmann, M., Muller, M. C., ... Hehlmann, R. (2009). Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. BLOOD, *115*(10), 1880-1885. [10]. http://www.ncbi.nlm.nih.gov/pubmed/19965667?dopt=Citation

Vancouver

Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. BLOOD. 2009;*115*(10):1880-1885. 10.

Bibtex

@article{88d3fe5d64974fc88e7ced072d1bb8e6,
title = "Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.",
abstract = "The role of allogeneic stem cell transplantation in chronic myeloid leukemia is being reevaluated. Whereas drug treatment has been shown to be superior in first line treatment, data on allo SCT as second line therapy after imatinib failure are scarce. Using an interim safety analysis of the German randomized CML-Study IV designed to optimize imatinib therapy by combination, dose-escalation and transplantation we here report on 84 patients consecutively transplanted according to predefined criteria (low EBMT score, imatinib failure, and advanced disease). Three year survival after transplantation of 56 patients in chronic phase was 91% (median follow-up 30 months). Transplantation related mortality was 8%. In a matched pair comparison of transplanted and non-transplanted patients, survival was not different. Three year survival after transplantation of 28 patients in advanced phase was 59%. 88% of transplanted patients achieved complete molecular remissions. We conclude that allo SCT could become the preferred second line option after imatinib failure for suitable patients with a donor. The study is registered at the National Institute of Health, ClinicalTrials.gov: NCT00055874.",
author = "Susanne Saussele and Michael Lauseker and Alois Gratwohl and Beelen, {Dietrich W} and Donald Bunjes and Rainer Schwerdtfeger and Hans-Jochem Kolb and Ho, {Anthony D} and Christiane Falge and Ernst Holler and Gunter Schlimok and Zander, {Axel R.} and Renate Arnold and Lothar Kanz and Robert Dengler and Claudia Haferlach and Brigitte Schlegelberger and Markus Pfirrmann and Muller, {Martin C} and Susanne Schnittger and Armin Leitner and Nadine Pletsch and Andreas Hochhaus and Joerg Hasford and Ruediger Hehlmann",
year = "2009",
language = "Deutsch",
volume = "*115*",
pages = "1880--1885",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

RIS

TY - JOUR

T1 - Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

AU - Saussele, Susanne

AU - Lauseker, Michael

AU - Gratwohl, Alois

AU - Beelen, Dietrich W

AU - Bunjes, Donald

AU - Schwerdtfeger, Rainer

AU - Kolb, Hans-Jochem

AU - Ho, Anthony D

AU - Falge, Christiane

AU - Holler, Ernst

AU - Schlimok, Gunter

AU - Zander, Axel R.

AU - Arnold, Renate

AU - Kanz, Lothar

AU - Dengler, Robert

AU - Haferlach, Claudia

AU - Schlegelberger, Brigitte

AU - Pfirrmann, Markus

AU - Muller, Martin C

AU - Schnittger, Susanne

AU - Leitner, Armin

AU - Pletsch, Nadine

AU - Hochhaus, Andreas

AU - Hasford, Joerg

AU - Hehlmann, Ruediger

PY - 2009

Y1 - 2009

N2 - The role of allogeneic stem cell transplantation in chronic myeloid leukemia is being reevaluated. Whereas drug treatment has been shown to be superior in first line treatment, data on allo SCT as second line therapy after imatinib failure are scarce. Using an interim safety analysis of the German randomized CML-Study IV designed to optimize imatinib therapy by combination, dose-escalation and transplantation we here report on 84 patients consecutively transplanted according to predefined criteria (low EBMT score, imatinib failure, and advanced disease). Three year survival after transplantation of 56 patients in chronic phase was 91% (median follow-up 30 months). Transplantation related mortality was 8%. In a matched pair comparison of transplanted and non-transplanted patients, survival was not different. Three year survival after transplantation of 28 patients in advanced phase was 59%. 88% of transplanted patients achieved complete molecular remissions. We conclude that allo SCT could become the preferred second line option after imatinib failure for suitable patients with a donor. The study is registered at the National Institute of Health, ClinicalTrials.gov: NCT00055874.

AB - The role of allogeneic stem cell transplantation in chronic myeloid leukemia is being reevaluated. Whereas drug treatment has been shown to be superior in first line treatment, data on allo SCT as second line therapy after imatinib failure are scarce. Using an interim safety analysis of the German randomized CML-Study IV designed to optimize imatinib therapy by combination, dose-escalation and transplantation we here report on 84 patients consecutively transplanted according to predefined criteria (low EBMT score, imatinib failure, and advanced disease). Three year survival after transplantation of 56 patients in chronic phase was 91% (median follow-up 30 months). Transplantation related mortality was 8%. In a matched pair comparison of transplanted and non-transplanted patients, survival was not different. Three year survival after transplantation of 28 patients in advanced phase was 59%. 88% of transplanted patients achieved complete molecular remissions. We conclude that allo SCT could become the preferred second line option after imatinib failure for suitable patients with a donor. The study is registered at the National Institute of Health, ClinicalTrials.gov: NCT00055874.

M3 - SCORING: Zeitschriftenaufsatz

VL - *115*

SP - 1880

EP - 1885

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 10

M1 - 10

ER -